1995Unpublished venueRequires access

Gemfibrozil vs fenofibrate in treating hyperlipidemia

Bi Chen, Shu Chen

Open publisher page 0 citations

Abstract

In 210 patients with hyperlipemia,109 patients(M60,F49;age 58±s 8 a) were treated with gemfibrozil 600 mg,po,bid×12 wk,and 101 patients(M66,F35;age 59±8a) were treated with fenofibrate 100 mg,po,bid×12 wk.Results shwed that in gemfibrozil group the levels of triglyceride(TG) and total cholesterol(TC) decreased 53.0%and 19.4% respectively, and high density lipoprotein cholesterol(HDL-ch) increased 26.8%(all P0.01).In fenofibrate group,the levels of TG and TC decreased 41.0% and 22.0%respectively and HDL-ch increased 22.0% (all P0.01).But the difference between the two groups was non significant (P0.05).No serious side effects were found during the therapeutic period,but 4 patients in gemfibrozil group and 5 patients in fenofibrate group had transient increase of GPT activity.

About this research paper

What this paper is about

In 210 patients with hyperlipemia,109 patients(M60,F49;age 58±s 8 a) were treated with gemfibrozil 600 mg,po,bid×12 wk,and 101 patients(M66,F35;age 59±8a) were treated with fenofibrate 100 mg,po,bid×12 wk.Results shwed that in gemfibrozil group the levels of triglyceride(TG) and total cholesterol(TC) decreased 53.0%and 19.4% respectively, and high density lipoprotein cholesterol(HDL-ch) increased 26.8%(all P0.01).In fenofibrate group,the levels of TG and TC decreased 41.0% and 22.0%respectively and HDL-ch increased 22.0% (all P0.01).But the difference between the two groups was non significant (P0.05).No serious side effects were found during the therapeutic period,but 4 patients in gemfibrozil group and 5 patients in fenofibrate group had transient increase of GPT activity.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In 210 patients with hyperlipemia,109 patients(M60,F49;age 58±s 8 a) were treated with gemfibrozil 600 mg,po,bid×12 wk,and 101 patients(M66,F35;age 59±8a) were treated with fenofibrate 100 mg,po,bid×12 wk.Results shwed that in gemfibrozil group the levels of triglyceride(TG) and total cholesterol(TC) decreased 53.0%and 19.4% respectively, and high density lipoprotein cholesterol(HDL-ch) increased 26.8%(all P0.01).In fenofibrate group,the levels of TG and TC decreased 41.0% and 22.0%respectively and HDL-ch increased 22.0% (all P0.01).But the difference between the two groups was non significant (P0.05).No serious side effects were found during the therapeutic period,but 4 patients in gemfibrozil group and 5 patients in fenofibrate group had transient increase of GPT activity.

Key concepts: Gemfibrozil, Fenofibrate, Internal medicine, Hyperlipidemia, Triglyceride, Endocrinology, Cholesterol, Medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Gemfibrozil vs fenofibrate in treating hyperlipidemia — Research Paper | ScholarLens